Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonolisib - Seattle Genetics

Drug Profile

Sonolisib - Seattle Genetics

Alternative Names: PX-866

Latest Information Update: 19 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Burnham Institute; University of Arizona; University of Pittsburgh
  • Developer Cascadian Therapeutics; Oncothyreon
  • Class Antineoplastics; Gonanes; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Glioblastoma; Head and neck cancer; Idiopathic pulmonary fibrosis; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Feb 2015 Oncothyreon and NCIC Clinical Trials Group, Canada completes a phase II trial in Glioblastoma (Recurrent, Second-line therapy or greater) in Canada (NCT01259869)
  • 13 Mar 2014 Oncothyreon completes phase I portion of a phase I/II trial in Malignant melanoma (combination therapy) in USA (NCT01616199)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top